Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03161418 · ClinicalTrials.gov registry record · Phase 1
Study of the Safety of KSP Heptapeptide (KSP-910638G)
A Phase 1 study, sponsored by University of Michigan.
- Completed
- Registry status
- Phase 1
- Development phase
- 26
- Enrollment target
NCT03161418 is a Phase 1 study that has completed, run by University of Michigan. The registered enrollment target is 26 participants.
The verdict
NCT03161418, a Phase 1 study, has completed, sponsored by University of Michigan.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 26 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety of orally administered KSP-910638G, a topically administered li-cor IRDye800CW labeled heptapeptide specific for human epithelial growth factor receptor 2 (HER2).
Interventions
- DRUG KSP-910638G, 0.4 mg
- DRUG KSP-910638G, 1.2 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2017-06-21 |
| Est. Completion | 2017-09-20 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03161418
The ClinicalTrials.gov registry entry for NCT03161418 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Michigan, which has 1,327 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which KSP-910638G, 0.4 mg is the first listed.
NCT03161418 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03161418 about?
NCT03161418 is a clinical study titled "Study of the Safety of KSP Heptapeptide (KSP-910638G)". The purpose of this study is to evaluate the safety of orally administered KSP-910638G, a topically administered li-cor IRDye800CW labeled heptapeptide specific for human epithelial growth factor receptor 2 (HER2).
What is the current status of trial NCT03161418?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 26 participants. The study started on 2017-06-21. Estimated completion is 2017-09-20.
What interventions are being tested in trial NCT03161418?
The interventions under investigation include: KSP-910638G, 0.4 mg (DRUG), KSP-910638G, 1.2 mg (DRUG).
Who is sponsoring clinical trial NCT03161418?
This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.